Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced FDA approval and U.S. launch of Generic Saxenda, the first generic GLP-1 for weight loss. The injection is indicated for adults with obesity or overweight and pediatric patients with obesity to help them lose weight and maintain it.

Ernie Richardsen, SVP at Teva, mentioned the significance of this launch as the fifth first-to-market entry of a Teva generic this year. This adds to Teva’s diverse complex generics portfolio, showcasing their ability to sustain a world-class Generics Powerhouse.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) operates in the U.S., Europe, and International Markets segments. The company develops, produces, and sells medicines across specialty, generics, and over-the-counter products. While TEVA shows investment potential, there are AI stocks with greater upside potential and lower downside risk in the market.

For more insights on undervalued AI stocks benefiting from Trump-era tariffs and onshoring trend, check out the free report on the best short-term AI stock. Visit Insider Monkey for more stock recommendations and insights on potential investments.

Read more at Yahoo Finance: Teva Pharmaceutical Industries (TEVA) Announces the FDA Approval and U.S. Launch of Generic Saxenda